Conatus Pharmaceuticals, a biotech focused on the development of novel medicines to treat liver disease, filed on Friday with the SEC to raise up to $69 million in an initial public offering. The San Diego, CA-based company, which was founded in 2005, does not generate any revenue from product sales. It plans to list on the NASDAQ under the symbol CNAT. Conatus Pharmaceuticals initially filed confidentially on May 10, 2013. Stifel and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
